SCHEMBL7270375

SCHEMBL7270375

O=C(O)c1ccc2oc3ccccc3c(=O)c2c1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.55
TBK1 Q9UHD2 1/20 0.54
MAOA P21397 6/20 0.53
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 2/20 0.52
GLA P06280 2/20 0.52
HPGD P15428 2/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
PGAM1 P18669 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAOB P27338 1/20 0.51
GAA P10253 2/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87587 0.89 TTR (0.47) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL27408664 0.84 MAOA (0.57) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL27617568 0.83 TTR (0.54) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL11367849 0.83 TTR (0.54) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL1987428 0.82 MAOA (0.62) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL11865624 0.82 TTR (0.44) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL6059629 0.79 ALDH1A1 (0.50) MAOAKDM4EALDH1A1GLAHPGD
SCHEMBL27697686 0.79 MAOA (0.58) TTRTBK1MAOAKDM4EALDH1A1
SCHEMBL32671605 0.77 KDM4E (0.57) MAOAKDM4EALDH1A1HPGDCYP3A4
SCHEMBL11809317 0.76 TTR (0.47) TTRTBK1MAOAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030138432-A1 Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs DRUG INNOVATION & DESIGN, INC. 2003-07-24 US disclosed
EP-1255567-A1 SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES Drug Innovation & Design, Inc. (US) 2002-11-13 EP disclosed
WO-2001036003-A2 SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES DRUG INNOVATION & DESIGN, INC. (US) 2001-05-25 WO disclosed
EP-0675145-B1 Xanthene polymers and copolymers GEN ELECTRIC (US) 1998-11-18 EP disclosed
US-5504184-A Xanthene polymers, and copolymers, and method for making GENERAL ELECTRIC COMPANY (US) 1996-04-02 US disclosed
US-5466777-A Xanthene polymers, and copolymers, and method for making GENERAL ELECTRIC COMPANY (US) 1995-11-14 US disclosed
EP-0675145-A2 Xanthene polymers and copolymers GENERAL ELECTRIC COMPANY (US) 1995-10-04 EP disclosed
US-4764584-A Radiation-sensitive polycondensates, their preparation, material coated therewith and the use thereof CIBA-GEIGY CORPORATION (US) 1988-08-16 US disclosed
US-4714669-A POLYAMIDES, POLYESTERS, OR POLYESTER AMIDES CIBA-GEIGY CORPORATION (US) 1987-12-22 US disclosed
US-3957986-A Antiviral compositions containing bis-basic esters and amides of xanthene and xanthone RICHARDSON-MERRELL INC. (US) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030138432-A1 Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs PAICS, ABCB1, ABCG2 TTR 3149/4885TBK1 2871/4885MAOA 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.